U.K. rules tighten M&A window for Stryker, Smith & Nephew deal

A U.K. law successfully thwarts overly aggressive acquisition deals from taking large bites out of the medical device industry in the country. Colloquially referred to as the "Put Up or Shut Up" rule, it sets a 28-day limit on foreign corporations trying to make an M&A deal. The tightened time frame forces executives to come to the table with concrete plans, a tall order in the industry, but if it's not ordered, the rule enforces a 6-month freeze-out, or scheduled "shut up" time. Speculation has surfaced of late that Stryker ($SYK) will make a bid for Smith & Nephew ($SN), after it showed interest but did not make a formal offer more than 6 months ago. With foreign companies increasingly eyeing of the value of U.K. businesses, the M&A law, put in place in 2011, has been used more often in the past year than ever before. Story (sub. req.)

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.